Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.73 |
| ▸ | IL6 | P05231 | 3/20 | 0.55 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2589596 | 0.93 | TLR7 (0.77) | TLR7IL6 | |
| SCHEMBL2588983 | 0.93 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL2586352 | 0.93 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL2583999 | 0.93 | TLR7 (0.73) | TLR7IL6 | |
| SCHEMBL2590406 | 0.91 | TLR7 (0.71) | TLR7IL6 | |
| SCHEMBL2588559 | 0.91 | TLR7 (0.71) | TLR7IL6 | |
| SCHEMBL2587349 | 0.91 | TLR7 (0.70) | TLR7IL6 | |
| SCHEMBL2587388 | 0.91 | TLR7 (0.70) | TLR7IL6 | |
| SCHEMBL2580421 | 0.90 | TLR7 (0.69) | TLR7IL6 | |
| SCHEMBL2591479 | 0.89 | TLR7 (0.69) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121693-B1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | claimed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | claimed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | claimed |
| EP-2121693-B1 | 8-OXOADENINE DERIVATIVES AS IMMUNO-MODULATORS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | disclosed |
| US-8067411-B2 | Compounds | ASTRAZENECA AB (SE) | 2011-11-29 | — | — | US | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300244-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300244-A1 | NOVEL COMPOUNDS | NPY1R, F12, NPY2R | TLR7 3711/4885IL6 4407/4885TLR8 4756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.